Drug Trial Radar · NCT06302491
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
May 27, 2024
Primary completion
Dec 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Kind Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.
Conditions
- β -Thalassemia
Interventions
AND017 capsulesDrug
Administer AND017 capsules once per day (QD)
AND017 PlaceboDrug
Administer AND017 matching placebo capsules once per day (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of different oral doses of AND017 in the treatment of β-thalassemia subjectsTime frame: From baseline to Week 24 or End of Treatment if discontinue early
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Maoming People's Hospital
Maoming, Guangdong, China · Recruiting
Liuzhou People's Hospital
Liuzhou, Guangxi, China · Recruiting
Guangxi Medical University No.1 Affiliated Hospital
Nanning, Guangxi, China · Recruiting
Hainan General Hospital
Haikou, Hainan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.